Effects of calorie restriction and IGF-1 receptor blockade on the progression of 22Rv1 prostate cancer xenografts

International Journal of Molecular Sciences

Volumn 14, Issue 7, 2013, Pages 13782-13795

  Galet, Colette ^a   Gray, Ashley ^b   Said, Jonathan W ^a   Castor, Brandon ^a   Wan, Junxiang ^c   Beltran, Pedro J ^d   Calzone, Franck J ^d   Elashoff, David ^a   Cohen, Pinchas ^c   Aronson, William J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d AMGEN INC   (United States)

Author keywords

Calorie restriction; IGF 1R blockade; Prostate cancer

Indexed keywords

CASPASE 3; CD31 ANTIGEN; GANITUMAB; INSULIN; INSULIN RECEPTOR; KI 67 ANTIGEN; PROTEIN KINASE B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C RECEPTOR; CANCER ANTIBODY; IGF1R PROTEIN, HUMAN; MONOCLONAL ANTIBODY; SOMATOMEDIN RECEPTOR; TUMOR PROTEIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CALORIC RESTRICTION; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DENSITOMETRY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; INSULIN BLOOD LEVEL; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; DRUG SCREENING; HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; SCID MOUSE; TUMOR CELL LINE; XENOGRAFT;

MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CALORIC RESTRICTION; CELL LINE, TUMOR; HETEROGRAFTS; HUMANS; MALE; MICE; MICE, SCID; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; RECEPTORS, SOMATOMEDIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879902635     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140713782     Document Type: Article

References (32)

1. Kohler, B.A.; Ward, E.; McCarthy, B.J.; Schymura, M.J.; Ries, L.A.; Eheman, C.; Jemal, A.; Anderson, R.N.; Ajani, U.A.; Edwards, B.K. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J. Natl. Cancer Inst. 2011, 103, 714-736.
2. Cohen, P.; Peehl, D.M.; Rosenfeld, R.G. The IGF axis in the prostate. Horm. Metab. Res. 1994, 26, 81-84.
3. Kojima, S.; Inahara, M.; Suzuki, H.; Ichikawa, T.; Furuya, Y. Implications of insulin-like growth factor-I for prostate cancer therapies. Int. J. Urol. 2009, 16, 161-167.
4. Chan, J.M.; Stampfer, M.J.; Giovannucci, E.; Gann, P.H.; Ma, J.; Wilkinson, P.; Hennekens, C.H.; Pollak, M. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998, 279, 563-566.
5. Stattin, P.; Rinaldi, S.; Biessy, C.; Stenman, U.H.; Hallmans, G.; Kaaks, R. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: A prospective study in a population-based nonscreened cohort. J. Clin. Oncol. 2004, 22, 3104-3112.
6. Chitnis, M.M.; Yuen, J.S.; Protheroe, A.S.; Pollak, M.; Macaulay, V.M. The type 1 insulin-like growth factor receptor pathway. Clin. Cancer Res. 2008, 14, 6364-6370.
7. Rodon, J.; DeSantos, V.; Ferry, R.J., Jr.; Kurzrock, R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials. Mol. Cancer Ther. 2008, 7, 2575-2588.
8. Wu, J.D.; Odman, A.; Higgins, L.M.; Haugk, K.; Vessella, R.; Ludwig, D.L.; Plymate, S.R. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin. Cancer Res. 2005, 11, 3065-3074.
9. Beltran, P.J.; Mitchell, P.; Chung, Y.A.; Cajulis, E.; Lu, J.; Belmontes, B.; Ho, J.; Tsai, M.M.; Zhu, M.; Vonderfecht, S. et al. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol. Cancer Ther. 2009, 8, 1095-1105.
10. Rowinsky, E.K.; Schwartz, J.D.; Zojwalla, N.; Youssoufian, H.; Fox, F.; Pultar, P.; Ludwig, D.L. Blockade of insulin-like growth factor type-1 receptor with cixutumumab (IMC-A12): A novel approach to treatment for multiple cancers. Curr. Drug Targets 2011, 12, 2016-2033.
11. Chi, K.N.; Gleave, M.E.; Fazli, L.; Goldenberg, S.L.; So, A.; Kollmannsberger, C.; Murray, N.; Tinker, A.V.; Pollak, M.N. A phase II pharmacodynamic study of pre-operative figitumumab in patients with localized prostate cancer. Clin. Cancer Res. 2012, 18, 3407-3413.
12. Scagliotti, G.V.; Novello, S. The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer Treat. Rev. 2012, 38, 292-302.
13. Konijeti, R.; Koyama, S.; Gray, A.; Barnard, R.J.; Said, J.W.; Castor, B.; Elashoff, D.; Wan, J.; Beltran, P.J.; Calzone, F.J. et al. Effect of a low-fat diet combined with IGF-1 receptor blockade on 22Rv1 prostate cancer xenografts. Mol. Cancer Ther. 2012, 11, 1539-1546.
14. Longo, V.D.; Fontana, L. Calorie restriction and cancer prevention: Metabolic and molecular mechanisms. Trends Pharmacol. Sci. 2010, 31, 89-98.
15. Hursting, S.D.; Smith, S.M.; Lashinger, L.M.; Harvey, A.E.; Perkins, S.N. Calories and carcinogenesis: Lessons learned from 30 years of calorie restriction research. Carcinogenesis 2010, 31, 83-89.
16. Giovannucci, E.; Liu, Y.; Platz, E.A.; Stampfer, M.J.; Willett, W.C. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int. J. Cancer 2007, 121, 1571-1578.
17. Ngo, T.H.; Barnard, R.J.; Tymchuk, C.N.; Cohen, P.; Aronson, W.J. Effect of diet and exercise on serum insulin, IGF-1, and IGFBP-1 levels and growth of LNCaP cells in vitro (United States). Cancer Causes Control 2002, 13, 929-935.
18. Blando, J.; Moore, T.; Hursting, S.D.; Jiang, G.; Saha, A.; Beltran, L.; Shen, J.; Repass, J.; Strom, S.S.; Digiovanni, J. Dietary energy balance modulates prostate cancer progression in Hi-Myc mice. Cancer Prev. Res. 2011, 4, 2002-2014.
19. Mukherjee, P.; Sotnikov, A.V.; Mangian, H.J.; Zhou, J.R.; Visek, W.J.; Clinton, S.K., Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. J. Natl. Cancer Inst. 1999, 91, 512-523.
20. Buschemeyer, W.C., III; Klink, J.C.; Mavropoulos, J.C.; Poulton, S.H.; Demark-Wahnefried, W.; Hursting, S.D.; Cohen, P.; Hwang, D.; Johnson, T.L.; Freedland, S.J. Effect of intermittent fasting with or without caloric restriction on prostate cancer growth and survival in SCID mice. Prostate 2010, 70, 1037-1043.
21. Desbois-Mouthon, C.; Baron, A.; Blivet-Van Eggelpoel, M.J.; Fartoux, L.; Venot, C.; Bladt, F.; Housset, C.; Rosmorduc, O. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: Rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin. Cancer Res. 2009, 15, 5445-5456.
22. Buck, E.; Gokhale, P.C.; Koujak, S.; Brown, E.; Eyzaguirre, A.; Tao, N.; Rosenfeld-Franklin, M.; Lerner, L.; Chiu, M.I.; Wild, R. et al., Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): Rationale for cotargeting IGF-1R and IR in cancer. Mol. Cancer Ther. 2010, 9, 2652-2664.
23. Bosma, G.C.; Custer, R.P.; Bosma, M.J. A severe combined immunodeficiency mutation in the mouse. Nature 1983, 301, 527-530.
24. Lee, C.; Safdie, F.M.; Raffaghello, L.; Wei, M.; Madia, F.; Parrella, E.; Hwang, D.; Cohen, P.; Bianchi, G.; Longo, V.D. Reduced levels of IGF-1 mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res. 2010, 70, 1564-1572.
25. Safdie, F.M.; Dorff, T.; Quinn, D.; Fontana, L.; Wei, M.; Lee, C.; Cohen, P.; Longo, V.D. Fasting and cancer treatment in humans: A case series report. Aging 2009, 1, 988-1007.
26. Fontana, L.; Partridge, L.; Longo, V.D. Extending healthy life span-From yeast to humans. Science 2010, 328, 321-326.
27. Cangemi, R.; Friedmann, A.J.; Holloszy, J.O.; Fontana, L. Long-term effects of calorie restriction on serum sex-hormone concentrations in men. Aging Cell 2010, 9, 236-242.
28. Fontana, L.; Klein, S.; Holloszy, J.O. Effects of long-term calorie restriction and endurance exercise on glucose tolerance, insulin action, and adipokine production. Age 2010, 32, 97-108.
29. Fontana, L. Calorie restriction and cardiometabolic health. Eur. J. Prev. Cardiol. 2008, 15, 3-9.
30. Redman, L.M.; Heilbronn, L.K.; Martin, C.K.; de Jonge, L.; Williamson, D.A.; Delany, J.P.; Ravussin, E. Metabolic and behavioral compensations in response to caloric restriction: Implications for the maintenance of weight loss. PLoS One 2009, 4, e4377.
31. Tolcher, A.W.; Sarantopoulos, J.; Patnaik, A.; Papadopoulos, K.; Lin, C.C.; Rodon, J.; Murphy, B.; Roth, B.; McCaffery, I.; Gorski, K.S. et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J. Clin. Oncol. 2009, 27, 5800-5807.
32. The R Project for Statistical Computing. Available online: http://www.r-project.org/ (accessed on 1 July 2013).